US2020360289A1PendingUtilityA1
Freeze-dried product and gas-filled microvesicles suspension
Est. expiryMay 15, 2039(~12.8 yrs left)· nominal 20-yr term from priority
A61K 49/223A61K 9/1277A61K 9/1271A61K 9/10A61K 9/19
66
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
Lipid formulation particularly for preparing stable gas-filled microvesicles, comprising distearoyl-phosphatidylcholine (DSPC), dipalmitoylphosphatidylethanolamine-PEG5000 (DPPE-PEG5000) and palmitic acid in an advantageous relative molar ratio. The formulation is useful in particular for therapeutic application with ultrasounds.
Claims
exact text as granted — not AI-modified1 . A freeze-dried formulation, for preparing gas-filled microvesicles, comprising a lipid mixture of DSPC, DPPE-PEG and palmitic acid in a respective molar amount of 65-85/4-10/8-22.
2 . The freeze-dried formulation of claim 1 wherein said respective molar amount is of 70-80/5-9/12-21.
3 . The freeze-dried formulation of claim 1 wherein said respective molar amount is of 72-76/6-8/15-20.
4 . The freeze-dried formulation of claim 1 wherein said respective molar amount is of 74 (+/−1)/7.5 (+/−0.5)/18.5(+/−1).
5 . The freeze-dried formulation of any of the preceding claims 1 to 4 further comprising a freeze-drying protective component.
6 . The freeze-dried formulation according to claim 5 , wherein freeze-drying protective component is PEG4000.
7 . The freeze-dried formulation according to claim 6 , wherein the weight of the lipid mixture is of from 0.08% to 0.3% with respect to the weight of PEG4000.
8 . The freeze-dried formulation according to claim 7 wherein said weight is of from 0.10% to 0.20%.
9 . The freeze-dried formulation according to claim 7 wherein said weight is of from 0.12% to 0.18% by weight
10 . The freeze-dried formulation according to claim 7 wherein said weight is of about 0.16%.
11 . A suspension of gas-filled microvesicles wherein said microvesicles comprise a mixture of DSPC, DPPE-PEG and palmitic acid in a respective molar amount of 65-85/4-10/8-22.
12 . The suspension of claim 11 wherein said respective molar amount is of 70-80/5-9/12-21.
13 . The suspension of claim 11 wherein said respective molar amount is of 72-76/6-8/15-20.
14 . The suspension of claim 11 wherein said respective molar amount is of 74 (+/−1)/7.5 (+/−0.5)/18.5(+/−1).Join the waitlist — get patent alerts
Track US2020360289A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.